Skip to Content
Merck
CN

Y0001046

Sevoflurane

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C4H3F7O
CAS Number:
Molecular Weight:
200.05
UNSPSC Code:
41116107
NACRES:
NA.24
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Sevoflurane, European Pharmacopoeia (EP) Reference Standard

SMILES string

FC(F)(F)C(OCF)C(F)(F)F

InChI

1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2

InChI key

DFEYYRMXOJXZRJ-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

sevoflurane

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Application

Sevoflurane EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

Storage Class

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inge K Herrmann et al.
Anesthesiology, 119(4), 901-906 (2013-07-23)
Sepsis remains a leading cause of death in intensive care units. There is growing evidence that volatile anesthetics have beneficial immunomodulatory effects on complex inflammation-mediated conditions. The authors investigated the effect of volatile anesthetics on the overall survival of mice
Bjorn Heyse et al.
Anesthesiology, 120(6), 1390-1399 (2014-02-26)
The authors studied the interaction between sevoflurane and remifentanil on bispectral index (BIS), state entropy (SE), response entropy (RE), Composite Variability Index, and Surgical Pleth Index, by using a response surface methodology. The authors also studied the influence of stimulation
Giovanni Landoni et al.
Journal of cardiothoracic and vascular anesthesia, 21(4), 502-511 (2007-08-07)
The authors performed a meta-analysis to investigate whether the cardioprotective effects of volatile anesthetics translate into decreased morbidity and mortality in patients undergoing cardiac surgery. It is commonly believed that the choice of the primary anesthetic agent does not result
Maj-Lis Lindholm et al.
Anesthesia and analgesia, 118(4), 782-787 (2014-03-22)
Preclinical data indicate that anesthesia and surgery may promote cancer growth. We previously found no increased risk of malignant disease within 5 years regarding duration of general anesthesia (TANESTH) and time with Bispectral Index (BIS) under 45 (TBIS < 45)
Jan Kehler et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(9), 1513-1518 (2014-07-06)
Phosphodiesterase 10A (PDE10A) plays a key role in the regulation of brain striatal signaling, and several pharmaceutical companies currently investigate PDE10A inhibitors in clinical trials for various central nervous system diseases. A PDE10A PET ligand may provide evidence that a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service